Latest Omni Bio Pharm Inc (OMBP) Headlines Om
Post# of 6
Posted On: 03/10/2014 9:42:15 PM
Latest Omni Bio Pharm Inc (OMBP) Headlines
Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Marketwire - Wed Nov 20, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced important results from new studies of its recombinant molecule, Fc-AAT.
Omni Bio Announces U.S. Patent Action for Its Recombinant Alpha-1 Antitrypsin Molecule
Marketwire - Wed Nov 06, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced that it has received a Notice of Allowance for its first U.S. patent for the composition of matter of its lead recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.
Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD").
Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.
Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.
Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.
Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Marketwire - Wed Nov 20, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced important results from new studies of its recombinant molecule, Fc-AAT.
Omni Bio Announces U.S. Patent Action for Its Recombinant Alpha-1 Antitrypsin Molecule
Marketwire - Wed Nov 06, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced that it has received a Notice of Allowance for its first U.S. patent for the composition of matter of its lead recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.
Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD").
Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.
Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.
Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.
(0)
(0)Omni Bio Pharm Inc (OMBP) Stock Research Links
Scroll down for more posts ▼